Acute Myocardial Infarction: Clinical Trials

73 trials for Acute Myocardial Infarction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 completed, 15 unknown, 6 terminated, 4 withdrawn. 73 Phase 2, 15 Phase 3, 13 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 273Completed 47, Unknown 15, Terminated 6, Withdrawn 4, Active not recruiting 1
Phase 315Completed 9, Unknown 4, Terminated 2
Phase 113Completed 8, Unknown 4, Terminated 1

Follow Acute Myocardial Infarction: new trials by email Literature Review of Acute Myocardial Infarction trials Research Report on Acute Myocardial Infarction

Trials (filtered) newest first · largest first

All 73 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
NL005 Middle Dose, NL005 High Dose, Placebo - Acute Myocardial Infarction
Phase 2CompletedBeijing Northland Biotech. Co., Ltd.902022-07-152024-06-21
Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
Tocilizumab, Dobutamine, NaCl 0.9% - Acute Myocardial Infarction, Cardiogenic Shock
Phase 2Active not recruitingCopenhagen University Hospital, Rigshospitalet1002022-03-132025-07-17
Ticagrelor Monotherapy After Stenting
Ticagrelor 90mg - Acute Myocardial Infarction
Phase 2CompletedVastra Gotaland Region2002021-12-142026-03-20
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
Low Dose, Middle Dose, High Dose - Acute Myocardial Infarction
Phase 2CompletedBeijing Northland Biotech. Co., Ltd.622020-11-232022-08-03
WJMSCs Anti-inflammatory Therapy in Acute Myocardial Infarction
Intravenous infusion placebo, Intravenous infusion WJMSCs - Acute Myocardial Infarction
Phase 2UnknownNavy General Hospital, Beijing2002020-11-012020-09-16
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack
BAY2433334, BAY2433334 matching placebo - Acute Myocardial Infarction
Phase 2CompletedBayer16012020-06-172023-04-05
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
Drug: Placebo, Drug: Injectable Thymosin beta 4 - Acute Myocardial Infarction, ST Elevation Myocardial Infarction
Phase 2WithdrawnRegeneRx Biopharmaceuticals, Inc.2019-07-012021-09-22
Stem Cell in Acute Myocardial Infarction
Mesenchymal Stem Cells - Acute Myocardial Infarction
Phase 1 / Phase 2CompletedPT. Prodia Stem Cell Indonesia42019-03-112022-06-14
Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
Dutogliptin Tartrate, Filgrastim Injectable Product, Placebos - Acute Myocardial Infarction, Acute Myocardial Ischemia
Phase 2CompletedRecardio, Inc.492018-12-072021-05-27
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
Selatogrel 8 mg, Selatogrel 16 mg - Acute Myocardial Infarction
Phase 2CompletedViatris Innovation GmbH482018-07-102026-07-29
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis
68Ga-NODAGA-E[c(RGDyK)]2 - Acute Myocardial Infarction
Phase 2CompletedCopenhagen University Hospital, Rigshospitalet422018-02-202020-07-14
Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea
Stage 1-Low dose VM202RY, Stage 1-Middle dose VM202RY, Stage 1-High dose VM202RY - Ischemic Heart Disease, Acute Myocardial Infarction
Phase 2WithdrawnHelixmith Co., Ltd.2018-01-252025-09-25
A Study of Acute Myocardial Infarction Using FDY-5301
FDY-5301, Placebo - Acute Myocardial Infarction, STEMI
Phase 2CompletedFaraday Pharmaceuticals, Inc.1202017-10-272026-01-16
Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients
Lysine Acetilsalicilate, Aspirin - Acute Myocardial Infarction
Phase 2 / Phase 3UnknownFundacion Investigacion Interhospitalaria Cardiovascular602016-10-012016-10-11
A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction
CSL_112, Placebo - Acute Myocardial Infarction, Moderate Renal Impairment
Phase 2CompletedCSL Behring832016-08-012020-06-11
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)
umbilical cord mesenchymal stem cells - Acute Myocardial Infarction, Myocardial Infarction
Phase 1 / Phase 2UnknownSouth China Research Center for Stem Cell and Regenerative Medicine642016-05-012016-01-28
EXCELLENT (EXpanded CELL ENdocardiac Transplantation)
PROTHERACYTES, Standard Treatment for CHF post AMI - Acute Myocardial Infarction
Phase 2CompletedCellProthera492016-02-102026-03-19
Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease
BMMSCs - Myocardial Infarction, Acute Myocardial Infarction
Phase 1 / Phase 2UnknownAcademy Military Medical Science, China2002015-11-012015-07-22
Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Single bolus of Placebo of CicloMulsion® (Neurovive)., Single bolus of cyclosporine A (CicloMulsion®, Neurovive) - Acute Myocardial Infarction
Phase 2WithdrawnHospices Civils de Lyon2015-09-012016-03-16
Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response
Colchimax®, Conventional treatment - Acute Myocardial Infarction
Phase 2CompletedUniversity Hospital, Montpellier442014-12-012017-01-18

Showing 20 of 73. Sign in to see all of them.

Narrower conditions

ST Elevation Myocardial Infarction (11)  ·  Myocardial Infarction (8)  ·  Heart Failure (6)  ·  Coronary Artery Disease (3)  ·  Inflammation (3)  ·  Shock, Cardiogenic (3)  ·  Cardiovascular Diseases (2)  ·  Myocardial Ischemia (2)  ·  Non-ST Elevated Myocardial Infarction (2)  ·  Reperfusion Injury (2)  ·  Vascular Diseases (2)  ·  Ventricular Remodeling (2)  ·  Acute Coronary Syndrome (1)  ·  Atherosclerosis (1)  ·  Blushing (1)

Broader conditions

Cardiovascular Diseases (32)  ·  Heart Diseases (30)  ·  Pathological Conditions, Signs and Symptoms (28)  ·  Vascular Diseases (28)  ·  Pathologic Processes (27)  ·  Ischemia (23)  ·  Myocardial Ischemia (23)  ·  Necrosis (23)  ·  Infarction (22)  ·  Myocardial Infarction (14)  ·  Arterial Occlusive Diseases (3)  ·  Arteriosclerosis (3)  ·  Coronary Disease (3)  ·  Pathological Conditions, Anatomical (3)  ·  Shock (3)

Interventions

Sodium Chloride (6)  ·  Filgrastim (3)  ·  Abciximab (2)  ·  Control Groups (2)  ·  Drug-Eluting Stents (2)  ·  Interleukin 1 Receptor Antagonist Protein (2)  ·  Melatonin (2)  ·  Nitric Oxide (2)  ·  Acetylcysteine (1)  ·  Aspirin (1)  ·  CSL112 (1)  ·  Cell- and Tissue-Based Therapy (1)  ·  Contraceptives, Oral (1)  ·  Dobutamine (1)  ·  Doxycycline (1)

Sponsors

Copenhagen University Hospital, Rigshospitalet (3)  ·  Virginia Commonwealth University (3)  ·  Beijing Northland Biotech. Co., Ltd. (2)  ·  CSL Behring (2)  ·  Russian Academy of Medical Sciences (2)  ·  Aarhus University Hospital Skejby (1)  ·  Abbott RDx Cardiometabolic (1)  ·  Academy Military Medical Science, China (1)  ·  Alberto Domínguez Rodríguez (1)  ·  Archemix Corp. (1)  ·  Assaf-Harofeh Medical Center (1)  ·  Azienda Unita Sanitaria Locale di Piacenza (1)  ·  Bayer (1)  ·  C. Michael Gibson, MS, MD (1)  ·  CellProthera (1)

Countries

United States (17)  ·  Germany (9)  ·  Denmark (8)  ·  Netherlands (8)  ·  Hungary (7)  ·  Italy (7)  ·  France (6)  ·  Poland (6)  ·  Belgium (5)  ·  Israel (5)  ·  Spain (5)  ·  United Kingdom (5)  ·  South Korea (4)  ·  Switzerland (4)  ·  Austria (3)

Top investigators

Antonio Abbate, MD, PhD (2)  ·  KeFei Dou (2)  ·  Alan Maisel, MD (1)  ·  Alberto Dominguez-Rodriguez, MD, PhD, FESC (1)  ·  Andreas M Zeiher, MD (1)  ·  Angel Leon, MD (1)  ·  Antonio Abbate, M.D., Ph.D. (1)  ·  Antonio L Bartorelli, MD (1)  ·  Ashok Seth, FRCP, FACC (1)  ·  Benjamin Van Tassell, PharmD (1)  ·  Bert Andersson, Prof MD (1)  ·  C. Michael Gibson, MS, MD (1)  ·  Christopher B Granger, MD (1)

Results publications

PMID 33217027, PMID 39531530, PMID 16807414, PMID 17123867, PMID 17161051, PMID 18535785, PMID 18598362, PMID 18845667, PMID 19131132, PMID 19539255, PMID 19781402, PMID 19910293, PMID 20102300, PMID 20576835, PMID 20598973, PMID 20961630, PMID 21127322, PMID 21132310, PMID 21299845, PMID 21372740, PMID 22236126, PMID 22449332, PMID 22503057, PMID 23281844, PMID 23453459, PMID 23596006, PMID 24431901, PMID 24467979, PMID 24495883, PMID 24925330, PMID 25121719, PMID 25482680, PMID 26098589, PMID 26296299, PMID 26321236, PMID 26709136, PMID 27267068, PMID 27659879, PMID 27881559, PMID 28533209, PMID 29634656, PMID 29800130, PMID 29921651, PMID 30033595, PMID 30580130, PMID 30602360, PMID 30957581, PMID 31151405, PMID 31870492, PMID 31982162

NIH funding

2005 (1), 2015 (1), 2018 (1), 2019 (1), R01HL103927 (1), R34HL121402 (1)